Skip to main content

Market Overview

Pfizer/BioNTech COVID-19 Vaccination Could Protect Pregnant Women, Newborns, Study In Israel Suggests: Reuters

Share:

According to a small study conducted in Israel, pregnant women vaccinated against COVID-19 could pass along protection to their babies, Reuters reported.

  • In the research conducted in February, antibodies were detected in all 20 women who got both doses of the Pfizer Inc (NYSE) / BioNTech SE (NASDAQ: BNTX) vaccine during their third trimester of pregnancy and in their newborns through placental transfer.
  • “Our findings highlight that vaccination of pregnant women may provide maternal and neonatal protection from SARS-CoV-2 infection,” the study said.
  • The authors noted the small size of the study and said further research was necessary to measure the effect of vaccination at different stages of pregnancy.
  • Pfizer/BioNTech said last month they had started a 4,000-volunteer international study to evaluate the safety and effectiveness of their COVID-19 vaccine in healthy pregnant women.
  • The trial will also assess whether vaccinated pregnant women transfer protective antibodies to their babies.
  • Price Action: PFE shares are down 0.03% at $35.82, and BNTX shares were trading 2.8% lower at $105.08 in market trading hours on the last check Wednesday.
 

Related Articles (PFE + BNTX)

View Comments and Join the Discussion!

Posted-In: COVID-19 Vaccine pregnancy ReutersBiotech News Health Care FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com